美国一般人群样本中的抗磷脂抗体检测：一项行政数据库研究。

Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study.

机构信息

McGill University, Division of Rheumatology, Montreal, Quebec, Canada.

University of Toronto Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada.

出版信息

Sci Rep. 2020 Feb 20;10(1):3102. doi: 10.1038/s41598-020-59990-5.

DOI:10.1038/s41598-020-59990-5

PMID:32080284

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7033098/

Abstract

We sought to characterized patterns of aPL testing in a large general population sample from the United States. Using Truven Health MarketScan laboratory data from 2010-2015 we identified individuals tested for lupus anticoagulant(LA), anti-cardiolipin (aCL), and anti-beta2-glycoprotein1(aGP1). Our research was approved by the McGill institutional review board (A04-M47-12B). We identified 33,456 individuals with at least one aPL test. Among these, only 6,391 (19%) had all three tests (LA, aCL, aGP1) performed. Confirmatory aPL testing was performed at least 12 weeks later in 77%, 45%, and 41% of initially positive LA, aCL, and aGP1, respectively. Of those re-tested after ≥12 weeks, only 255 (10.6%) were found to have a confirmatory positive aPL test. These findings highlight that aPL testing may often be incompletely performed. Further investigations will be required to better understand the low rate of a confirmatory positive aPL test ≥12 weeks after the initial test.

摘要

我们试图描述美国一个大型普通人群样本中抗磷脂抗体（aPL）检测的模式。使用 2010-2015 年 Truven Health MarketScan 实验室数据，我们确定了接受狼疮抗凝剂（LA）、抗心磷脂（aCL）和抗β2-糖蛋白 1（aGP1）检测的个体。我们的研究得到了麦吉尔机构审查委员会（A04-M47-12B）的批准。我们确定了 33456 名至少进行过一次 aPL 检测的个体。在这些人中，只有 6391 人（19%）进行了所有三项检测（LA、aCL、aGP1）。最初阳性的 LA、aCL 和 aGP1 分别有 77%、45%和 41%在至少 12 周后进行了确认性 aPL 检测。在≥12 周后重新检测的人中，只有 255 人（10.6%）的确认性 aPL 检测结果为阳性。这些发现表明，aPL 检测可能经常不完全进行。需要进一步研究以更好地了解在初始检测后≥12 周时确认性阳性 aPL 检测的低发生率。